The efficacy of the combination of dihydroergotamine (10 mg) with acetylsalicylic acid (80 mg) (DHE + ASA) in the prophylaxis of migraine was studied in a double-blind, placebo-controlled crossover trial (8 weeks twice). Of 45 patients who entered the study, 38 completed it. The number of attacks was significantly (p = 0.003) reduced during active treatment (11.5 ± 6.2) compared with placebo (16.6 ± 9.9). The mean duration, the mean severity, and the mean score for symptomatic acute medication of attacks did not differ significantly. The overall assessment made by the patients themselves was in favor of DHE + ASA (p = 0.001). These results indicate a moderately beneficial effect of the dihydroergotamine/low-dose acetylsalicylic acid combination in migraine prophylaxis.
CouchJRHassaneinFR.Platelet aggregability in migraine.Neurology1977;27:843–8.
2.
DeshmukhSVMeyerJSMoucheRJ.Platelet dysfunction in migraine: effect of self medication with aspirin.Thrombos Haemost1976;36:319–24.
3.
DeshmukhSVMeyerJS.Cyclic changes in platelet dynamics and the pathogenesis and prophylaxis of migraine.Headache1977;17:101–8.
4.
HaningtonEJonesRJ.Migraine: a platelet disorder.Lancet1981;2:720–3.
5.
D'AndreaGToldoMCortelazzoSFerro-MiloneF.Platelet activity in migraine.Headache1982;22:207–12.
6.
D'AndreaGToldoMCananziAFerro-MiloneF.Study of platelet activation in migraine. Control by low doses of aspirin.Stroke1984;15:271–5.
7.
O'NeilBPMannJD.Aspirin prophylaxis in migraine.Lancet1978;2:1179–81.
8.
MaselBEChessonALPetersBHLevinHSAlperinJB.Platelet antagonists in migraine prophylaxis. A clinical trial using aspirin and dipyridamole.Headache1980;20:13–8.
9.
MoellerHC.Langzeit prophylaxe der migräne mit acetylsalicylsäure.Med Klin1983;78:201–4.
10.
Hosman-BenjaminseSLBolhuisPA.Migraine and platelet aggregation in patients treated with low dose acetylsalicylic acid.Headache1986;26:282–4.
11.
SpuhlerO.dihydroergotamine (DHE 45) als sympathicolyticum in der inneren Medizin.Schweiz Meal Wochenschr1946;76:125–7.
12.
KallosPKallos-DeffnerL.The use of ergot derivatives in prophylaxis and therapy of migraine.Prog Allergy1952;3:485–99.
13.
ArnalJ.Cent cas de migraine traitées par la DHE pendant un mois à 10 ans.Gaz Med Fr1979;86:164–8.
14.
GirardM.Action de la dihydroergotamine utilisée seule dans la prevention de la migraine.J Med Lyon1969;50:1–15.
15.
HeyckH.Prophylactic treatment of migraine with ergot compounds. In:DallesioDJDalsgaard-NielsenTDiamondS.Proceedings of the international headache symposium.Vol 1.Basel: Sandoz1971:99–101.
16.
ZekertFSchemperMNeumannK.Acetylsalicylic acid in combination with dihydroergotamine for preventing thromboembolism.Haemostasis1982;11:149–53.
17.
BoismareFRichardO.Etude des effets de l'association d'aspirine et de dihydroergotamine sur les contractures de la carotide de lapin provoquées par la noradrenaline ou la serotonine.1986.Paper available from Jacques Chick,Laboratoire Millot-Solac, 16 avenue George V, 75008 Paris, France.
18.
HanleySPBevanJCockbillSRHeptinstallS.Differential inhibition by low dose aspirin of human venous prostacyclin synthesis and platelet thromboxane synthesis.Lancet1981;1:969–71.
19.
JakubowskiJAStampferMJVaillancourtRFaigelDDeykinD.Low-dose enteric-coated aspirin: A practical approach to continuous-release low-dose aspirin and presystemic acetylation of human platelet cyclooxygenase.J Lab Clin Med1986;108:616–21.
20.
Ad Hoc Committee on Classification of Headache.JAMA1962;179:717–8.
21.
BousserMGBaronJC.Drug trials in migraine. The clinician's view on end points.Neuroepidemiology1987;6:228–33.
22.
HillsMArmitageP.The two period cross over clinical trial.Br J Clin Pharmacol1979;8:7–20.
23.
SmithMJerusalemFRhynerKIslerH.Salicylate prophylaxis in migraine.Arch Suisses Neurol Neurochir Psych1984;135:273–5.
24.
AylwardMChazotGMaddockJ.Schott B. Le traitement des migraines matinales. Correlation clinique et biocinétique d'une dihydroergotamine h libération programmée.Presse Med1984;13:1617–9.
25.
JorgensenRS.BC 105, et nyt migräenemittel (BC 105 ein neues Migränemittel).Ugeskr Laeg1972;134:2266–8.
26.
NeumannMDemarezJPHarmeyJLLe BastardBCauquilJ.Prévention des crises migraineuses par la dihydroergotamine. Etude en double aveugle contre placebo.Vie Med1984;65:869–70.
27.
MartucciNMannaVMattesiPTroianiGManzoniCLanfranchiM.Ergot derivatives in the prophylaxis of migraine: a multicentric study with a timed-release dihydroergotamine formulation.Cephalalgia1983;3(suppl 1):151–5.
28.
LindbladBBergquistDHednerU.The effect of dihydroergotamine on the haemostatic system.Thromb Haemost1985;50(1):67.
29.
ThebaultJJ.Study of interactions between aspirin and dihydroergotamine on platelet aggregability in normal healthy volunteers.1986.Paper available from Jacques Chick,Laboratoire Millot-Solac, 16 avenue George V, 75008 Paris, France.
30.
De MetzJEVan ZwietenPA.Differential effects of dihydroergotamine on the circulatory actions of arterial and venous dilators in the rat.J Cardiovasc Pharm1981;3:217–27.
31.
SinzingerH.The effect of dihydroergotamine on various platelet function tests and venous prostacyclin formation in men.Thromb Haemost1985;53:285–6.
32.
PradalierAKerdelhueBDryJ.Beta-endorphine et dihydroergotamine au cours de la migraine.Therapie1984;39:323–32.
33.
RomitiAMartellettiPGalloMFPerrottaRAGiacovazzoM.Nuovi contributi su le preove di estinzione nelle cefalee essenziali. I. II test con acetilsalicilato di lisina.Boll Soc Ital Biol Sper1983;59(8):1130–3.
